soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction SOUL: Cuts by 14% in People with Type 2 Diabetes Cardiovascular Outcomes Trial (CVOT) |

This framing is particularly important in PCOS, where restoration of ovulation during treatment may increase the likelihood of unintended conception before patients recognize that fertility has improved

Dysregulation of metabolic pathways by carnitine palmitoyl-transferase 1 plays a key role in central nervous system disorders: experimental evidence based on animal models

That said, if you experience unusual symptoms after starting or changing doses of either medication, including agitation, rapid heartbeat, muscle twitching, or excessive sweating, contact your provider promptly

(Lifestyle changes were implemented as well in both groups.) The average change in body weight from week zero to week 68 was -14.9% in the semaglutide group